Vasa Therapeutics Receives FDA IND Clearance to Advance Novel Small Molecule VS-041 for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
Phase 1c Clinical Trial to Begin Immediately ENCINITAS, Calif. and WROCLAW, Poland, Oct. 13, 2025 /PRNewswire/ -- Vasa Therapeutics, ("Vasa"), a private, clinical stage biotechnology company developing novel therapies for cardiovascular and metabolic aging, today announced that the U.S....
